CG Oncology, Inc. (CGON) shareholders
Close on Nov 13, 2026Market cap $6.59BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RTW Investments, LP Joint filing with Roderick Wong (9.70%) | 8,514,590 | 9.70% | 13G (passive) amendment | Jun 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 6,720,389 | 8.00% | 13G (passive) | Mar 31, 2026 |
| Xiangmin Cui Joint filing with Decheng Capital Global Life Sciences Fund IV, L.P. (7.00%), Decheng Capital Management IV (Cayman), LLC (7.00%) | 6,371,669 | 8.40% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 6,023,696 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (7.20%), Wellington Group Holdings LLP (7.20%) and 1 more | 5,512,779 | 6.90% | 13G (passive) | Sep 30, 2025 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (6.00%), Wellington Investment Advisors Holdings LLP (6.00%) and 1 more | 5,324,751 | 6.00% | 13G (passive) amendment | Jun 30, 2026 |
| Juliet Tammenoms Bakker Joint filing with Patrick G. Enright (6.00%) | 4,662,268 | 6.00% | 13D (active) | Sep 11, 2025 |
| SONG, Hong Fang | 4,211,341 | 5.50% | 13G (passive) amendment | Dec 31, 2024 |
| FMR LLC Joint filing with Abigail P. Johnson (5.10%) | 3,856,261 | 5.10% | 13G (passive) | Jun 30, 2025 |
| Kissei Pharmaceutical Co., Ltd. | 3,543,533 | 5.30% | 13G (passive) | Jan 29, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CGON | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 8,514,590 | 9.61% | $604.96M | +1,529,782 | 5.16% |
| T. Rowe Price Investment Management, Inc. | 6,616,899 | 7.46% | $470.13M | −103,490 | 0.31% |
| Decheng Capital LLC | 6,371,669 | 7.19% | $452.71M | – | 61.87% |
| BlackRock, Inc. | 6,256,288 | 7.06% | $444.51M | +1,192,108 | 0.01% |
| Wellington Management Group Llp | 5,324,751 | 6.01% | $378.32M | −46,481 | 0.07% |
| FMR LLC | 4,161,493 | 4.69% | $295.67M | +396,649 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 3,805,010 | 4.29% | $270.35M | +152,030 | 0.03% |
| TCG Crossover Management, LLC | 3,670,206 | 4.14% | $260.77M | – | 6.27% |
| Vanguard Portfolio Management LLC | 3,465,197 | 3.91% | $246.20M | +370,099 | 0.01% |
| State Street Corp | 3,437,590 | 3.88% | $244.24M | +790,536 | 0.01% |
| Vanguard Capital Management LLC | 3,316,793 | 3.74% | $235.66M | +283,168 | 0.01% |
| Foresite Capital Management VI LLC | 2,369,574 | 2.67% | $168.36M | +148,100 | 26.20% |
| Geode Capital Management, LLC | 2,153,277 | 2.43% | $153.02M | +556,413 | 0.01% |
| Seven Fleet Capital Management LP | 1,886,236 | 2.13% | $134.02M | +1,810,478 | 22.12% |
| EcoR1 Capital, LLC | 1,494,300 | 1.69% | $106.17M | +392,300 | 5.16% |
| DV Trading LLC | 1,439,393 | 1.62% | $102.27M | – | 3.35% |
| Avidity Partners Management LP | 1,398,948 | 1.58% | $99.40M | +110,000 | 15.92% |
| Alliancebernstein L.P. | 1,374,149 | 1.55% | $93.00M | +84,062 | 0.03% |
| Franklin Resources Inc | 1,312,880 | 1.48% | $93.28M | −194,125 | 0.02% |
| Morgan Stanley | 1,177,109 | 1.33% | $83.63M | +656,896 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 227 | 94M | 100.0% | 34 / 93 | 72 / 37 | 14M | 8M |
| Q1 2026 | 233 | 88M | 99.7% | 65 / 81 | 61 / 23 | 25M | 13M |
| Q4 2025 | 195 | 83M | 93.3% | 43 / 72 | 50 / 20 | 14M | 9M |
| Q3 2025 | 176 | 78M | 87.9% | 34 / 54 | 57 / 19 | 9M | 7M |
| Q2 2025 | 162 | 76M | 85.7% | 40 / 76 | 29 / 19 | 14M | 9M |
| Q1 2025 | 142 | 71M | 79.8% | 27 / 62 | 33 / 24 | 8M | 3M |
| Q4 2024 | 140 | 66M | 74.7% | 37 / 59 | 27 / 17 | 19M | 5M |
| Q3 2024 | 121 | 52M | 58.9% | 26 / 60 | 19 / 15 | 15M | 4M |
| Q2 2024 | 111 | 43M | 48.8% | 32 / 45 | 18 / 17 | 10M | 6M |
| Q1 2024 | 96 | 39M | 43.9% | 96 / 0 | 0 / 0 | 39M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
328 funds held CGON in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CGON | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 2,860,428 | 3.23% | $203.63M | 0.53% | Jul 31, 2026 |
| T. Rowe Price Capital Appreciation Fund | 2,574,868 | 2.90% | $182.94M | 0.26% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,383,134 | 2.69% | $169.32M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,894,091 | 2.14% | $134.58M | 0.16% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,812,932 | 2.05% | $128.81M | 1.20% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,720,068 | 1.94% | $122.21M | 0.06% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,114,695 | 1.26% | $79.20M | 0.54% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 860,026 | 0.97% | $61.10M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 806,808 | 0.91% | $57.44M | 0.17% | Jul 31, 2026 |
| Fidelity Small Cap Growth Fund | 797,441 | 0.90% | $56.77M | 0.65% | Jul 31, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 744,793 | 0.84% | $52.92M | 0.23% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 681,220 | 0.77% | $48.40M | 0.31% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 658,981 | 0.74% | $46.82M | 0.48% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 593,262 | 0.67% | $42.15M | 0.28% | Jun 30, 2026 |
| Small Cap Growth Fund | 554,416 | 0.63% | $39.47M | 0.71% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Arthur Kuan | Chief Executive Officer, Director | 200,763 | 0.23% | Apr 16, 2026 |
| Isabel Kalofonos | Chief Commercial Officer | – | – | Oct 19, 2026 |
| James M. Detore | Chief Financial Officer | – | – | Apr 16, 2026 |
| Ambaw Bellete | President and COO | – | – | Apr 16, 2026 |
| Joshua F. Patterson | See Remarks | – | – | Apr 16, 2026 |
| Vijay Kasturi | Chief Medical Officer | 1,315 | 0.00% | Apr 16, 2026 |
| Bob Lapetina | See Remarks | – | – | Aug 6, 2025 |
| Corleen M. Roche | CFO | 2,000 | 0.00% | Apr 16, 2025 |
| Leonard E. Post | Director | 0 | – | Oct 19, 2026 |
| James Mulay | Director | 0 | – | Jul 14, 2026 |
| Brian Guan-Chyun Liu | Director | 1,886,236 | 2.13% | Jun 29, 2026 |
| Susan E. Graf | Director | – | – | Jun 5, 2026 |
| Victor Edward Tong Jr | Director | – | – | Jun 5, 2026 |
| Christina Rossi | Director | – | – | Jun 5, 2026 |
| Hong Fang Song | Director | 7,039,077 | 7.94% | Sep 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Leonard E. Post Director | Oct 15, 2026 | Sale(10b5-1 plan) | −500 | $62.48 | $31.24K | 0 |
| Leonard E. Post Director | Oct 15, 2026 | Sale(10b5-1 plan) | −500 | $61.65 | $30.83K | 500 |
| Leonard E. Post Director | Oct 15, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Sep 15, 2026 | Sale(10b5-1 plan) | −1,000 | $72.98 | $72.98K | 0 |
| Leonard E. Post Director | Sep 15, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Aug 14, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Aug 14, 2026 | Sale(10b5-1 plan) | −1,000 | $74.54 | $74.54K | 0 |
| Leonard E. Post Director | Jul 15, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Jul 15, 2026 | Sale(10b5-1 plan) | −1,000 | $71.17 | $71.17K | 0 |
| James Mulay Director | Jul 10, 2026 | Sale(10b5-1 plan) | −24,165 | $75.16 | $1.82M | 0 |
| James Mulay Director | Jul 10, 2026 | Option exercise | +24,165 | $26.63 | $643.51K | 24,165 |
| Brian Guan-Chyun Liu Director | Jun 25, 2026 | Buy | +371,085 | $66.87 | $24.81M | 1,886,236 |
| Leonard E. Post Director | Jun 24, 2026 | Option exercise | +5,000 | $0.60 | $3.00K | 5,000 |
| Leonard E. Post Director | Jun 24, 2026 | Sale(10b5-1 plan) | −5,000 | $70.00 | $350.00K | 0 |
| Leonard E. Post Director | Jun 22, 2026 | Option exercise | +5,000 | $0.60 | $3.00K | 5,000 |
| Leonard E. Post Director | Jun 22, 2026 | Sale(10b5-1 plan) | −5,000 | $65.00 | $325.00K | 0 |
| James Mulay Director | Jun 15, 2026 | Sale(10b5-1 plan) | −654 | $60.12 | $39.32K | 0 |
| James Mulay Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,310 | $60.12 | $78.76K | 0 |
| James Mulay Director | Jun 15, 2026 | Option exercise | +1,310 | $12.59 | $16.49K | 1,310 |
| James Mulay Director | Jun 15, 2026 | Option exercise | +654 | $3.72 | $2.43K | 654 |
| Leonard E. Post Director | Jun 4, 2026 | Sale(10b5-1 plan) | −1,000 | $54.50 | $54.50K | 0 |
| Leonard E. Post Director | Jun 4, 2026 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| James Mulay Director | Apr 17, 2026 | Sale(10b5-1 plan) | −15,600 | $73.01 | $1.14M | 0 |
| James Mulay Director | Apr 17, 2026 | Option exercise | +15,600 | $36.63 | $571.43K | 15,600 |
| James Mulay Director | Mar 16, 2026 | Sale(10b5-1 plan) | −1,310 | $63.50 | $83.19K | 0 |
| James Mulay Director | Mar 16, 2026 | Sale(10b5-1 plan) | −654 | $63.50 | $41.53K | 0 |
| James Mulay Director | Mar 16, 2026 | Option exercise | +654 | $3.72 | $2.43K | 654 |
| James Mulay Director | Mar 16, 2026 | Option exercise | +1,310 | $12.59 | $16.49K | 1,310 |
| Arthur Kuan Chief Executive Officer, Director | Mar 12, 2026 | Option exercise | +64,612 | $1.72 | $111.13K | 200,763 |
| Arthur Kuan Chief Executive Officer, Director | Mar 12, 2026 | Tax withholding | −1,847 | $60.15 | $111.10K | 198,916 |
| Arthur Kuan Chief Executive Officer, Director | Mar 4, 2026 | Tax withholding | −2,871 | $61.61 | $176.88K | 136,151 |
| Arthur Kuan Chief Executive Officer, Director | Mar 4, 2026 | Option exercise | +102,871 | $1.72 | $176.94K | 139,022 |
| James Mulay Director | Jan 9, 2026 | Option exercise | +10,491 | $12.59 | $132.08K | 10,491 |
| James Mulay Director | Jan 9, 2026 | Option exercise | +654 | $3.72 | $2.43K | 654 |
| James Mulay Director | Jan 9, 2026 | Sale(10b5-1 plan) | −654 | $44.16 | $28.88K | 0 |
| James Mulay Director | Jan 9, 2026 | Sale(10b5-1 plan) | −10,491 | $52.99 | $555.92K | 0 |
| Leonard E. Post Director | Nov 17, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Nov 17, 2025 | Sale(10b5-1 plan) | −1,000 | $41.43 | $41.43K | 0 |
| Leonard E. Post Director | Oct 13, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Oct 13, 2025 | Sale(10b5-1 plan) | −1,000 | $43.25 | $43.25K | 0 |
| James Mulay Director | Oct 9, 2025 | Option exercise | +5,903 | $3.72 | $21.96K | 5,903 |
| James Mulay Director | Oct 9, 2025 | Sale(10b5-1 plan) | −5,903 | $43.99 | $259.67K | 0 |
| Leonard E. Post Director | Sep 30, 2025 | Sale(10b5-1 plan) | −5,000 | $40.09 | $200.45K | 0 |
| Leonard E. Post Director | Sep 30, 2025 | Option exercise | +5,000 | $0.60 | $3.00K | 5,000 |
| James Mulay Director | Sep 29, 2025 | Sale(10b5-1 plan) | −12,755 | $39.19 | $499.87K | 0 |
| James Mulay Director | Sep 29, 2025 | Option exercise | +12,755 | $1.82 | $23.21K | 12,755 |
| James Mulay Director | Sep 19, 2025 | Sale(10b5-1 plan) | −3,574 | $38.99 | $139.35K | 0 |
| James Mulay Director | Sep 19, 2025 | Option exercise | +3,574 | $1.82 | $6.50K | 3,574 |
| James Mulay Director | Sep 18, 2025 | Sale(10b5-1 plan) | −19,112 | $39.01 | $745.56K | 0 |
| James Mulay Director | Sep 18, 2025 | Option exercise | +19,112 | $1.82 | $34.78K | 19,112 |
| Leonard E. Post Director | Sep 15, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Sep 15, 2025 | Sale(10b5-1 plan) | −1,000 | $35.10 | $35.10K | 0 |
| Brian Guan-Chyun Liu Director | Sep 11, 2025 | Buy | +1,515,151 | $33.00 | $50.00M | 1,515,151 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −12,342 | $30.47 | $376.06K | 14,673 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −4,095 | $31.42 | $128.66K | 10,578 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −7,465 | $32.64 | $243.66K | 3,113 |
| James Mulay Director | Sep 5, 2025 | Option exercise | +27,015 | $0.60 | $16.21K | 27,015 |
| James Mulay Director | Sep 5, 2025 | Sale(10b5-1 plan) | −3,113 | $33.22 | $103.41K | 0 |
| Leonard E. Post Director | Sep 3, 2025 | Option exercise | +1,000 | $0.60 | $600 | 1,000 |
| Leonard E. Post Director | Sep 3, 2025 | Sale(10b5-1 plan) | −1,000 | $28.00 | $28.00K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CG Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 129,916 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Leonard E. Post Director | Oct 15, 2026 | 3,000 | $185.52K | Oct 15, 2026 | Exercise of Stock Options |
| Ambaw Bellete Officer | Sep 21, 2026 | 30,787 | $2.34M | Sep 21, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Sep 17, 2026 | 6,532 | $499.70K | Sep 17, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Sep 11, 2026 | 826 | $61.95K | Sep 11, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Sep 2, 2026 | 29,630 | $2.30M | Sep 2, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 31, 2026 | 50,000 | $3.78M | Aug 31, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 27, 2026 | 5,789 | $459.56K | Aug 27, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 25, 2026 | 10,551 | $839.34K | Aug 25, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 24, 2026 | 5,762 | $458.19K | Aug 24, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 19, 2026 | 100,000 | $7.95M | Aug 19, 2026 | Exercised Shares |
| Ambaw Bellete Officer | Aug 17, 2026 | 52,438 | $4.03M | Aug 17, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 14, 2026 | 19,364 | $1.45M | Aug 14, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 13, 2026 | 25,989 | $1.97M | Aug 13, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 12, 2026 | 32,137 | $2.53M | Aug 12, 2026 | Stock Option Exercise |
| Ambaw Bellete Officer | Aug 11, 2026 | 50,000 | $3.81M | Aug 11, 2026 | Stock Option Exercise |
See a number that looks wrong?